VALN•benzinga•
Valneva SE Announces That The EMA Has Started A Review Of Valneva's Single-Dose Live Attenuated Chikungunya Vaccine IXCHIQ Based On Reports Of Serious Adverse Events In Elderly People
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 7, 2025 by benzinga